Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer

Hepatology. 2021 Apr;73(4):1399-1418. doi: 10.1002/hep.31466.

Abstract

Background and aims: Programmed death 1 (PD-1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T-cell dysfunction in liver cancer, however, remain largely elusive.

Approach and results: We performed a comprehensive mRNA profiling of cluster of differentiation 8 (CD8) T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector, and exhausted, tumor-specific CD8 T cells. Subsequently, we functionally validated the role of identified genes in T-cell exhaustion. Our results reveal a unique transcriptome signature of exhausted T cells and demonstrate that up-regulation of the inhibitory immune receptor T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitor motif domains (TIGIT) represents a hallmark in the process of T-cell exhaustion in liver cancer. Compared to PD-1, expression of TIGIT more reliably identified exhausted CD8 T cells at different stages of their differentiation. In combination with PD-1 inhibition, targeting of TIGIT with antagonistic antibodies resulted in synergistic inhibition of liver cancer growth in immunocompetent mice. Finally, we demonstrate expression of TIGIT on tumor-infiltrating CD8 T cells in tissue samples of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets of patients based on differential expression of TIGIT on tumor-specific T cells.

Conclusions: Our transcriptome analysis provides a valuable resource for the identification of key pathways involved in T-cell exhaustion in patients with liver cancer and identifies TIGIT as a potential target in checkpoint combination therapies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Animals
  • Bile Duct Neoplasms / genetics*
  • Bile Duct Neoplasms / immunology*
  • Bile Duct Neoplasms / pathology
  • Biomarkers, Tumor / genetics
  • CD8-Positive T-Lymphocytes / immunology*
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / genetics*
  • Carcinoma, Hepatocellular / immunology*
  • Carcinoma, Hepatocellular / pathology
  • Cell Line, Tumor
  • Cholangiocarcinoma / genetics*
  • Cholangiocarcinoma / immunology*
  • Cholangiocarcinoma / pathology
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Female
  • Gene Expression Profiling / methods
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / genetics*
  • Liver Neoplasms / immunology*
  • Liver Neoplasms / pathology
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Receptors, Immunologic / antagonists & inhibitors
  • Receptors, Immunologic / genetics*
  • Transcriptome*
  • Treatment Outcome
  • Tumor Burden / drug effects

Substances

  • Biomarkers, Tumor
  • Immune Checkpoint Inhibitors
  • Pdcd1 protein, mouse
  • Programmed Cell Death 1 Receptor
  • Receptors, Immunologic
  • T cell Ig and ITIM domain protein, mouse
  • TIGIT protein, human